Trial Profile

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegozafermin (Primary)
Indications Fibrosis; Non-alcoholic steatohepatitis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms ENLIGHTEN-Fibrosis
Sponsors 89bio

Most Recent Events

21 Mar 2025 Planned primary completion date changed from 1 Dec 2026 to 1 Feb 2029.
27 Feb 2025 According to a 89bio media release, the company expects topline data from the histology cohorts of ENLIGHTEN-Fibrosis n the first half of 2027.
09 May 2024 According to a 89bio media release, the topline results from this study anticipated in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com